From march 30th 2009 bta ann.''Daiichi Sankyo exercise right to...

From march 30th 2009 bta ann.


''Daiichi Sankyo exercise right to market CS-8958 in Japan
Biota Holdings Limited (ASX:BTA) today announced that Daiichi Sankyo, the co-owner
of the long acting neuraminidase inhibitor (LANI) CS-8958, has signed a contract to
manufacture and market the product in Japan, pending the successful completion of
the pivotal Phase III clinical studies and on obtaining registration approval.''


So the statement from DS today is they have completed the Phase 3 studies and are seeking to gain approval. This is massive news. Surely it means it has been successful and BTA must make a annoucement of this to the market. At a time the world is screaming for more antivirals. This could be a PR bonaza. Will BTA capitalise on it.!!!

I hope so.

Why are we being kept in the dark when DS clearly state they have completed Phase 3.